It might be expensive to do from scratch, but it's a type of effort that with the right pitch, someone like Google could be persuaded to host. For humanitarian reasons and the tax write off.
-
Why not? I can't easily find how much data is in the SRA as of now...
It might be expensive to do from scratch, but it's a type of effort that with the right pitch, someone like Google could be persuaded to host. For humanitarian reasons and the tax write off.
-
If you think about it rationally, there's no way you can have a centralised single resource for sequence data volumes which are doubling every year or so.Leave a comment:
-
According to the email it will be around for some months yet ...
Not clear as yet what will happen to the already submitted data.Leave a comment:
-
I did wonder about that myself but then decided who has the time to fake up official NCBI communication?
But anyhow, I've had independent confirmation from several sources that it is true.Leave a comment:
-
Omg!
Taking on the ad hoc centralization of such an important shared database resource at the forefront of such an important developing scientific field and then just dropping it from open access sight is the pits! NCBI, I am pointing fingers at you. At the very least, local, institutional science libraries and infrastructure should have been primed to develop their own SRA capacities, (and then staffed by their own employees of course) as your SRA curation was clearly not founded upon reliable scientific funding committments.Leave a comment:
-
Short Read Archive Canned
More details here:
Where will you submit your data now?
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Leave a comment: